Brandon Beylo: Biotech stocks show strength despite FOMC meeting volatility

Brandon Beylo: Biotech stocks show strength despite FOMC meeting volatility
Biotech stocks rise despite FOMC volatility

Brandon Beylo highlights strong performance in the biotech sector, observing that biotech stocks demonstrated resilience despite volatility around the FOMC meeting.

Beylo suggests that such strength often points to the emergence of new market leaders, and shares that he is beginning to build a basket of biotech names.

Beylo has recently commented on other assets, noting that gold traded below its 200-day average for the first time since 2023, which he viewed as a potential long-term buying opportunity here. He previously suggested that gold prices could bottom near $3,800 per ounce before recovering here. These observations come as he shifts focus to building positions in biotech stocks.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.